Data confirm absence of side effects and benefit of the simpler treatment schedule:
The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment. The DHA/PQP combination is very well tolerated with no significant side effects. These notable results were presented at the 57th Annual Meeting of the American Society of Tropical Medicine & Hygiene.Read it all.